David Risinger
Stock Analyst at Leerink Partners
(3.58)
# 817
Out of 4,944 analysts
168
Total ratings
65.17%
Success rate
13.97%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $174.42 | -12.28% | 4 | May 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $395.92 | +27.05% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $561.55 | +48.52% | 8 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $201.47 | +2.25% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $47.85 | +52.56% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $22.08 | +212.57% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.91 | +170.73% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $15.30 | +187.58% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $31.55 | +384.94% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $12.42 | -19.48% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $2.07 | -3.38% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $20.74 | +126.67% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $289.33 | +9.91% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $17.14 | -35.82% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $660.49 | -30.66% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $65.13 | -35.51% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $120.14 | -24.26% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $25.16 | +90.78% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.96 | -16.39% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.36 | +295.30% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $117.12 | +50.27% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $10.41 | +53.70% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $23.66 | +90.19% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $7.17 | +388.15% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $17.81 | +130.21% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $152.44 | +14.14% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $36.46 | +39.88% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $17.21 | -53.52% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $82.71 | +7.60% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $9.40 | -68.09% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $28.63 | -44.11% | 9 | Apr 2, 2020 |
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $174.42
Upside: -12.28%
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $395.92
Upside: +27.05%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $561.55
Upside: +48.52%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $201.47
Upside: +2.25%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $47.85
Upside: +52.56%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $22.08
Upside: +212.57%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.91
Upside: +170.73%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $15.30
Upside: +187.58%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $31.55
Upside: +384.94%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $12.42
Upside: -19.48%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $2.07
Upside: -3.38%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $20.74
Upside: +126.67%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $289.33
Upside: +9.91%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $17.14
Upside: -35.82%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $660.49
Upside: -30.66%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $65.13
Upside: -35.51%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $120.14
Upside: -24.26%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.16
Upside: +90.78%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.96
Upside: -16.39%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.36
Upside: +295.30%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $117.12
Upside: +50.27%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $10.41
Upside: +53.70%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $23.66
Upside: +90.19%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $7.17
Upside: +388.15%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $17.81
Upside: +130.21%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $152.44
Upside: +14.14%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $36.46
Upside: +39.88%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $17.21
Upside: -53.52%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $82.71
Upside: +7.60%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $9.40
Upside: -68.09%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $28.63
Upside: -44.11%